医薬品原薬 (API) の中国市場：予測と分析 (2018年)
Market for Active Pharmaceutical Ingredients in China - Forecast and Analysis 2018
|出版日||ページ情報||英文 160 Pages
|医薬品原薬 (API) の中国市場：予測と分析 (2018年) Market for Active Pharmaceutical Ingredients in China - Forecast and Analysis 2018|
|出版日: 2019年09月01日||ページ情報: 英文 160 Pages||
中国は世界第2位の医薬品市場として台頭しており、医薬品・バイオテクノロジー部門の成長が最も速い新興市場のひとつです。中国の医薬品原薬 (API) 市場規模は、アジア太平洋地域の中で日本に次いで第2位となっています。2017年においてはアジア太平洋のAPI産業の収益の20%を中国が構成しました。
当レポートでは、中国における医薬品原薬 (API) 市場について調査し、API市場のイントロダクション、世界市場、アジア太平洋市場、および中国市場における分析と予測、主要企業のプロファイルなどを提供しています。
In recent years, China has emerged as the second biggest pharmaceutical market in the world. It is today one of the fastest emerging markets in the pharmaceutical and biotechnology sector globally. A rapidly-ageing population along with a thriving middle class has opened up this market for tremendous opportunities for active pharmaceutical ingredients (APIs) sector. With the Chinese government setting its sights on becoming an important innovator of a variety of pharmaceutical products.
The market for active pharmaceutical ingredients in China is the second largest API market in the entire Asia Pacific region, second only to Japan. In 2017 alone, China accounted for over 20% of the revenues for the Asia Pacific API industry. With many national pharmaceutical companies dominating the domestic pharmaceutical industry, the Chinese market has recently witnessed the entry of many large foreign pharmaceutical companies setting up their plants in the country. However, China faces a major issue with intellectual property rights protection, which has resulted in a low level of market penetration for branded drugs, allowing generics to dominate the domestic market.
With the government determined to tighten regulations governing intellectual property rights, it is expected that the market for APIs in China is going to witness a major boost in the coming years.
Aruvian Research analyzes the market for APIs in China in its research report Market for Active Pharmaceutical Ingredients in China - Forecast and Analysis 2018. The data covered in this report ranges from 2008 till 2020. Let us take a look at what the report focusses on.
The report begins with an introduction to Active Pharmaceutical Ingredients and then moves on to briefly analyze the global market for active pharmaceutical ingredients. We include an overview of the global market for APIs and a look at the global market's revenues.
Section D of the report analyzes the market for active pharmaceutical ingredients in Asia Pacific through an industry overview, industry revenues, and a look at the various therapeutic applications of APIs in the Asia Pacific region. Impacts on the Asia Pacific active pharmaceutical ingredients market are also analyzed.
With section E, we begin our analysis of the market for active pharmaceutical ingredients in China. This section analyzes the industry through basic statistics and industry revenues. Industry segmentation through the biotech segment and the synthetic API market in China is included in the report, along with a forecast of the industry till 2020.
An analysis of the major industry players, both global and domestic, are included in the report. The major players are analyzed through a business segment profile, a look at their major products and services, and a SWOT analysis. The analysis looks at nearly 25 major companies operating in the Chinese API market.
Research methodology for the report concludes this comprehensive report on the market for active pharmaceutical ingredients in China till 2020.